Loci Orthopaedics
Summary
- Company developing its innovative InDx Implant System for thumb base joint arthritis - Focused on a painful and disabling condition with increasing prevalence in patient population - Funds to support clinical programs, regulatory submissions and future commercialisation 17 July 2024 Galway, Ireland | Loci Orthopaedics Ltd, an orthopaedic medical device company, today announced the successful closing of an oversubscribed 12.8 million Series A financing. Thumb base joint arthritis is a highly and increasingly prevalent condition which is estimated to actively affect up to 5% of the US and EU population and 100 million people worldwide1. The InDx implant replicates the functional biomechanics of the thumb base joint, with the aim of restoring natural motion for those affected by this painful and disabling condition. Thumb arthritis can cause severe pain, swelling, and decreased strength and range of motion, making it difficult to do simple tasks, such as turning doorknobs and opening jars. It is estimated that 5% of the population have symptomatic thumb base joint arthritis which causes significant hand pain and has a major negative impact on quality of life.